Reports
Sale
Global Stuttering Therapeutics Market Size, Growth, Analysis, Forecast: By Treatment: Speech Therapy, Stuttering Devices, Cognitive Behavioural Therapy, Parent Child Interaction, Drug Therapy; By Type: Developmental Stuttering, Neurogenic Stuttering; By End User: Hospitals, Others; Regional Analysis; Supplier Landscape; 2024-2032
Global Stuttering Therapeutics Market Outlook
The global stuttering therapeutics market size was valued at USD 42.18 million in 2023, driven by the increasing number of stuttering cases across the globe. The market size is anticipated to grow at a CAGR of 14% during the forecast period of 2024-2032 to achieve a value of USD 137.17 million by 2032.
Stuttering Therapeutics: Introduction
Childhood onset fluency order or stuttering is a speech disorder that disrupts the rate and rhythm of fluency. It is characterized by the repetition, prolongations, and broken words. Motor movements like blinking, tremors, jerks or breathing movements may persist in rare cases.
Developmental stuttering is the most common type of stuttering, which is mostly observed in young kids while learning speech and language skills. It occurs when the speech and language abilities is not compatible with its verbal requirements. Neurogenic stuttering is another category and it occur post head trauma, brain injury or a stroke. Speech therapy, drug therapy, self-help groups and electronic devices are commonly used to treat stuttering.
Global Stuttering Therapeutics Market Analysis
The United States accounts for the highest number of stuttering cases, ranging from 1.15% to 2.52%. Europe falls in the range between 0.58% to 2.2%. Australia and Africa stand at 0.33%–1.8% and 1.03% respectively . In Asia, countries like Iran, Iraq, Pakistan, Nepal, and few parts of India observe stuttering cases quite commonly when compared to others.
During the historical period, stuttering therapeutics have been in a high demand in the North American region, with high prevalence of cases. However, it is anticipated that over the forecast period, stuttering therapeutics market share would rise in both the European and Asia Pacific regions due to the growing awareness and technological advancements around stuttering treatments.
Stuttering prevalence varies due to multiple factors, including gender, age, number of languages known, and financial status. Research indicates that the average male to female stuttering ratio is around 4:1. Stuttering in bilinguals lies at 2.8%, whereas it is comparatively lower in monolinguals (1.8%). Researchers are getting more inclusive and innovative with different type of therapeutics to cater to all the components elevating the stuttering cases.
The global market for stuttering therapeutics has witnessed significant growth over the past few yeats. Speech therapy is the most successful category of stuttering treatments. Various behavioural therapies like cognitive behavioural therapy (CBT) and neuromodulation are also beneficial. In the pharmacologic treatment, dopamine blocking medications have confirmed efficacy against stuttering. D2 dopamine blockers are effective in decreasing the symptoms of stuttering. Moreover, they have a lower risk of motor system side effects. Medications with calcium channel blockers can also help. With further research and technological advancements, we can observe efficient and economical treatments for stuttering.
Global Stuttering Therapeutics Market Segmentation
Market Breakup by Treatment
- Speech Therapy
- Stuttering Devices
- Cognitive Behavioural Therapy
- Parent Child Interaction
- Drug Therapy
Market Breakup by Type
- Developmental Stuttering
- Neurogenic Stuttering
Market Breakup by End User
- Hospitals
- Specialty Clinics
- Homecare
- Others
Market Breakup by Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Global Stuttering Therapeutics Market Overview
Earlier, there were no FDA approved medications to treat stuttering, but that has changed over the years. Ecopipam is an investigational drug developed by Emalex Biosciences Inc. It is designed to treat stuttering symptoms and has shown fair endurance in the clinical trials. Ecopipam works by blocking the action of Dopamine at D1 receptor. The super-sensitivity of this receptor can be linked to the repetitive and compulsive behaviours associated with stuttering as well as Tourette syndrome.
As we are living in a digital world, development of speech therapy apps has led to a gradual increase in the stuttering therapeutics market growth. Speech therapy applications are designed for all age groups, ranging from toddlers to adults. Children can engage with entertaining voice playbacks and interactive games to improve their speech. Adults can use the apps to develop conversational abilities or to get back on track after a stroke. Stamurai, Stamma, Splingo, Articulation Station are some examples of the applications.
Electronic devices are the newest addition to the stuttering therapeutics global market. An electronic device called SpeechEasy reduces stuttering by manipulating auditory feedback. It works via time delays and frequency shifts. A group of people who stutter were examined on several parameters like device settings, ear-placements, speaking tasks, and cognitive variables. With this device, a significant reduction in stuttering was observed. Therefore, we can assume that with the development of such electronic devices, the therapeutics market for stuttering will observe notable progression in the coming years.
Global Stuttering Therapeutics Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Emalex Biosciences Inc.
- Auspex Pharmaceuticals (Teva Pharmaceutical Industries Ltd.)
- GSK plc.
- Johnson & Johnson Services, Inc.
- Merck & Co., Inc.
- Pfizer Inc.
- Siemens Healthcare GmbH
- Novartis AG
- AstraZeneca
- AbbVie Inc.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Treatment |
|
| Breakup by Type |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Stuttering Therapeutics Market Overview
3.1 Global Stuttering Therapeutics Market Historical Value (2017-2023)
3.2 Global Stuttering Therapeutics Market Forecast Value (2024-2032)
4 Global Stuttering Therapeutics Market Landscape
4.1 Global Stuttering Therapeutics Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Stuttering Therapeutics Product Landscape
4.2.1 Analysis by Treatment
4.2.2 Analysis by Types
5 Global Stuttering Therapeutics Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter’s Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Stuttering Therapeutics Market Segmentation
6.1 Global Stuttering Therapeutics Market by Treatment
6.1.1 Market Overview
6.1.2 Speech Therapy
6.1.3 Stuttering Devices
6.1.4 Cognitive Behavioural Therapy
6.1.5 Parent Child Interaction
6.1.6 Drug Therapy
6.2 Global Stuttering Therapeutics Market by Type
6.2.1 Market Overview
6.2.2 Developmental Stuttering
6.2.3 Neurogenic Stuttering
6.3 Global Stuttering Therapeutics Market by End User
6.3.1 Market Overview
6.3.2 Hospitals
6.3.3 Specialty Clinics
6.3.4 Homecare
6.3.5 Others
6.4 Global Stuttering Therapeutics Market by Region
6.4.1 Market Overview
6.4.2 North America
6.4.3 Europe
6.4.4 Asia Pacific
6.4.5 Latin America
6.4.6 Middle East and Africa
7 North America Stuttering Therapeutics Market
7.1 Market Share by Country
7.2 United States of America
7.3 Canada
8 Europe Stuttering Therapeutics Market
8.1 Market Share by Country
8.2 United Kingdom
8.3 Germany
8.4 France
8.5 Italy
8.6 Others
9 Asia Pacific Stuttering Therapeutics Market
9.1 Market Share by Country
9.2 China
9.3 Japan
9.4 India
9.5 ASEAN
9.6 Australia
9.7 Others
10 Latin America Stuttering Therapeutics Market
10.1 Market Share by Country
10.2 Brazil
10.3 Argentina
10.4 Mexico
10.5 Others
11 Middle East and Africa Stuttering Therapeutics Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.4 Nigeria
11.5 South Africa
11.6 Others
12 Patent Analysis
12.1 Analysis by Type of Patent
12.2 Analysis by Publication year
12.3 Analysis by Issuing Authority
12.4 Analysis by Patent Age
12.5 Analysis by CPC Analysis
12.6 Analysis by Patent Valuation
12.7 Analysis by Key Players
13 Grants Analysis
13.1 Analysis by year
13.2 Analysis by Amount Awarded
13.3 Analysis by Issuing Authority
13.4 Analysis by Grant Application
13.5 Analysis by Funding Institute
13.6 Analysis by NIH Departments
13.7 Analysis by Recipient Organization
14 Funding Analysis
14.1 Analysis by Funding Instances
14.2 Analysis by Type of Funding
14.3 Analysis by Funding Amount
14.4 Analysis by Leading Players
14.5 Analysis by Leading Investors
14.6 Analysis by Geography
15 Partnership and Collaborations Analysis
15.1 Analysis by Partnership Instances
15.2 Analysis by Type of Partnership
15.3 Analysis by Leading Players
15.4 Analysis by Geography
16 Regulatory Framework
16.1 Regulatory Overview
16.1.1 US FDA
16.1.2 EU EMA
16.1.3 INDIA CDSCO
16.1.4 JAPAN PMDA
16.1.5 Others
17 Supplier Landscape
17.1 Emalex Biosciences Inc.
17.1.1 Financial Analysis
17.1.2 Product Portfolio
17.1.3 Demographic Reach and Achievements
17.1.4 Mergers and Acquisitions
17.1.5 Certifications
17.2 Auspex Pharmaceuticals (Teva Pharmaceutical Industries Ltd.)
17.2.1 Financial Analysis
17.2.2 Product Portfolio
17.2.3 Demographic Reach and Achievements
17.2.4 Mergers and Acquisitions
17.2.5 Certifications
17.3 GSK plc.
17.3.1 Financial Analysis
17.3.2 Product Portfolio
17.3.3 Demographic Reach and Achievements
17.3.4 Mergers and Acquisitions
17.3.5 Certifications
17.4 Johnson & Johnson Services, Inc.
17.4.1 Financial Analysis
17.4.2 Financial Portfolio
17.4.3 Demographic Reach and Achievements
17.4.4 Mergers and Acquisitions
17.4.5 Certifications
17.5 Merck & Co., Inc.
17.5.1 Financial Analysis
17.5.2 Product Portfolio
17.5.3 Demographic Reach and Achievements
17.5.4 Mergers and Acquisitions
17.5.5 Certifications
17.6 Pfizer Inc.
17.6.1 Financial Analysis
17.6.2 Product Portfolio
17.6.3 Demographic Reach and Achievements
17.6.4 Mergers and Acquisitions
17.6.5 Certifications
17.7 Siemens Healthcare GmbH
17.7.1 Financial Analysis
17.7.2 Product Portfolio
17.7.3 Demographic Reach and Achievements
17.7.4 Mergers and Acquisitions
17.7.5 Certifications
17.8 Novartis AG
17.8.1 Financial Analysis
17.8.2 Product Portfolio
17.8.3 Demographic Reach and Achievements
17.8.4 Mergers and Acquisitions
17.8.5 Certifications
17.9 AstraZeneca
17.9.1 Financial Analysis
17.9.2 Product Portfolio
17.9.3 Demographic Reach and Achievements
17.9.4 Mergers and Acquisitions
17.9.5 Certifications
17.10 AbbVie Inc.
17.10.1 Financial Analysis
17.10.2 Product Portfolio
17.10.3 Demographic Reach and Achievements
17.10.4 Mergers and Acquisitions
17.10.5 Certifications
18 Global Stuttering Therapeutics Market - Distribution Model (Additional Insight)
18.1 Overview
18.2 Potential Distributors
18.3 Key Parameters for Distribution Partner Assessment
19 Key Opinion Leaders (KOL) Insights (Additional Insight)
20 Company Competitiveness Analysis (Additional Insight)
20.1 Very Small Companies
20.2 Small Companies
20.3 Mid-Sized Companies
20.4 Large Companies
20.5 Very Large Companies
21 Payment Methods (Additional Insight)
21.1 Government Funded
21.2 Private Insurance
21.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The market attained a value of about USD 42.18 million in 2023 due to the rising stuttering cases across the globe.
The market is anticipated to grow at a CAGR of 14% during the forecast period of 2024-2032, likely to reach a market value of USD 137.17 million by 2032.
The market demand is expected to grow with the rising awareness and technical developments on stuttering therapeutics.
With speech therapy and behavioural therapy preferred as a type of treatment for stuttering. Currently, drug therapy, electronic devices and mobile applications are looked upon as a contemporary and effective treatment.
Stuttering treatments include speech therapy, stuttering devices, cognitive behavioural therapy, parent child interaction, and drug therapy.
People can experience developmental stuttering at a young age while neurogenic stuttering mostly occurs in adults, after a head trauma, brain injury or a stroke.
The major regions of the market include North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. North America is currently leading the global market.
The types of stuttering treatments include speech therapies, cognitive behavioural therapies, drug therapies. Electronic devices and apps are also used.
The end users in the market include hospitals, specialty clinics, and homecare, among others.
Key players involved in the market are Emalex Biosciences Inc., Auspex Pharmaceuticals (Teva Pharmaceutical Industries Ltd.), GSK plc., Johnson & Johnson Services, Inc., Merck & Co. Inc., Pfizer Inc., Siemens Healthcare GmbH, Novartis AG, AbbVie Inc., and AstraZeneca.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 2969
$2699
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 5499
$4999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 6599
$5999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 7699
$6999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER